INR 53.16
(-0.91%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.72 Billion INR | -0.97% |
2022 | 1.73 Billion INR | 32.22% |
2021 | 1.31 Billion INR | -1.97% |
2020 | 1.34 Billion INR | 31.88% |
2019 | 1.01 Billion INR | 71.96% |
2018 | 591.62 Million INR | -33.93% |
2017 | 895.47 Million INR | -3.62% |
2016 | 929.06 Million INR | 5.22% |
2015 | 883 Million INR | 11.01% |
2014 | 795.4 Million INR | 9.91% |
2013 | 723.67 Million INR | -1.74% |
2012 | 736.45 Million INR | 36.32% |
2011 | 540.24 Million INR | 160.25% |
2010 | 207.58 Million INR | 22.74% |
2009 | 169.12 Million INR | 141.39% |
2008 | 70.06 Million INR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | -1.32 Billion INR | -177.1% |
2023 Q1 | - INR | -100.0% |
2023 FY | 1.72 Billion INR | -0.97% |
2023 Q2 | 1.15 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 Q4 | 1.72 Billion INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2022 FY | 1.73 Billion INR | 32.22% |
2022 Q4 | 1.73 Billion INR | 0.0% |
2022 Q3 | - INR | -100.0% |
2022 Q2 | 1.11 Billion INR | 0.0% |
2021 Q2 | 1.59 Billion INR | 0.0% |
2021 Q4 | 1.31 Billion INR | 0.0% |
2021 Q1 | - INR | -100.0% |
2021 Q3 | - INR | -100.0% |
2021 FY | 1.31 Billion INR | -1.97% |
2020 FY | 1.34 Billion INR | 31.88% |
2020 Q1 | - INR | -100.0% |
2020 Q2 | 246.68 Million INR | 0.0% |
2020 Q4 | 1.34 Billion INR | 0.0% |
2019 Q3 | - INR | -100.0% |
2019 FY | 1.01 Billion INR | 71.96% |
2019 Q4 | 1.01 Billion INR | 0.0% |
2019 Q1 | - INR | -100.0% |
2019 Q2 | 218.12 Million INR | 0.0% |
2018 FY | 591.62 Million INR | -33.93% |
2018 Q1 | - INR | -100.0% |
2018 Q4 | 591.62 Million INR | 0.0% |
2017 Q4 | 444.49 Million INR | -18.26% |
2017 FY | 895.47 Million INR | -3.62% |
2017 Q3 | 543.77 Million INR | 0.0% |
2016 Q4 | 929.06 Million INR | 0.0% |
2016 FY | 929.06 Million INR | 5.22% |
2015 FY | 883 Million INR | 11.01% |
2015 Q4 | 883 Million INR | 0.0% |
2014 FY | 795.4 Million INR | 9.91% |
2014 Q4 | 795.4 Million INR | 0.0% |
2013 FY | 723.67 Million INR | -1.74% |
2013 Q4 | 723.67 Million INR | 0.0% |
2012 FY | 736.45 Million INR | 36.32% |
2012 Q4 | 736.45 Million INR | 0.0% |
2011 Q4 | 540.24 Million INR | 0.0% |
2011 FY | 540.24 Million INR | 160.25% |
2010 FY | 207.58 Million INR | 22.74% |
2009 FY | 169.12 Million INR | 141.39% |
2008 FY | 70.06 Million INR | 0.0% |
2008 Q4 | 70.06 Million INR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Amrutanjan Health Care Limited | 783.82 Million INR | -119.716% |
Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -496.327% |
Caplin Point Laboratories Limited | 3.5 Billion INR | 50.873% |
FDC Limited | 3.7 Billion INR | 53.57% |
Gufic Biosciences Limited | 5.59 Billion INR | 69.246% |
Hikal Limited | 12.99 Billion INR | 86.747% |
Ind-Swift Laboratories Limited | 2.28 Billion INR | 24.778% |
IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 72.789% |
Kilitch Drugs (India) Limited | 643.88 Million INR | -167.469% |
Medico Remedies Limited | 438.24 Million INR | -292.975% |
Nectar Lifesciences Limited | 11.21 Billion INR | 84.648% |
Par Drugs and Chemicals Limited | 159.79 Million INR | -977.775% |
RPG Life Sciences Limited | 1.38 Billion INR | -24.778% |
Sequent Scientific Limited | 8.27 Billion INR | 79.186% |
Shilpa Medicare Limited | 12.93 Billion INR | 86.683% |
Sigachi Industries Limited | 2.53 Billion INR | 31.963% |
Themis Medicare Limited | 1.88 Billion INR | 8.759% |
Unichem Laboratories Limited | 8.06 Billion INR | 78.657% |
Venus Remedies Limited | 1.39 Billion INR | -23.649% |
Wanbury Limited | 3.15 Billion INR | 45.423% |
ZIM Laboratories Limited | 2.08 Billion INR | 17.233% |
Lupin Limited | 96.23 Billion INR | 98.21% |
Innova Captab Limited | 4.89 Billion INR | 64.852% |
Ind-Swift Limited | 13.45 Billion INR | 87.198% |
Bajaj HealthCare Limited | 4.86 Billion INR | 64.62% |
Aurobindo Pharma Limited | 152.2 Billion INR | 98.869% |
Solara Active Pharma Sciences Limited | 14.09 Billion INR | 87.779% |
AstraZeneca Pharma India Limited | 3.66 Billion INR | 52.96% |
Mangalam Drugs & Organics Limited | 1.97 Billion INR | 12.858% |
Morepen Laboratories Limited | 4.45 Billion INR | 61.384% |
Laurus Labs Limited | 42.71 Billion INR | 95.968% |
Aarti Drugs Limited | 11.5 Billion INR | 85.03% |
Glenmark Life Sciences Limited | 5.18 Billion INR | 66.759% |
Alembic Limited | 1.43 Billion INR | -20.256% |
Alembic Pharmaceuticals Limited | 16.27 Billion INR | 89.417% |
Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 97.355% |
Vaishali Pharma Limited | 371.16 Million INR | -363.998% |
Aarti Pharmalabs Limited | 8.25 Billion INR | 79.127% |
Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -480.33% |
Jubilant Pharmova Limited | 61.27 Billion INR | 97.189% |
Eris Lifesciences Limited | 38.26 Billion INR | 95.5% |
Windlas Biotech Limited | 1.76 Billion INR | 2.298% |
Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 99.062% |
Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -60.271% |
Orchid Pharma Limited | 3.84 Billion INR | 55.199% |
Albert David Limited | 1.15 Billion INR | -49.742% |
Hester Biosciences Limited | 3.59 Billion INR | 52.091% |
Sakar Healthcare Limited | 1.26 Billion INR | -36.327% |
Suven Pharmaceuticals Limited | 2.03 Billion INR | 15.34% |
Procter & Gamble Health Limited | 2.56 Billion INR | 32.759% |
Divi's Laboratories Limited | 18.99 Billion INR | 90.931% |
Mankind Pharma Limited | 23.87 Billion INR | 92.787% |
Neuland Laboratories Limited | 5.49 Billion INR | 68.679% |
J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 83.917% |
Zydus Lifesciences Limited | 71.79 Billion INR | 97.601% |
Wockhardt Limited | 39.87 Billion INR | 95.68% |
Bal Pharma Limited | 2.51 Billion INR | 31.422% |
Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.39% |
Bliss GVS Pharma Limited | 2.1 Billion INR | 18.335% |
Alkem Laboratories Limited | 48.6 Billion INR | 96.457% |
Valiant Laboratories Limited | 1.05 Billion INR | -62.737% |
Ajanta Pharma Limited | 10.71 Billion INR | 83.92% |
Bafna Pharmaceuticals Limited | 652.27 Million INR | -164.026% |
Granules India Limited | 22.95 Billion INR | 92.497% |
Medicamen Biotech Limited | 940.36 Million INR | -83.14% |
Ipca Laboratories Limited | 33.74 Billion INR | 94.896% |
Brooks Laboratories Limited | 248.6 Million INR | -592.752% |
Syncom Formulations (India) Limited | 1.16 Billion INR | -47.8% |
Piramal Enterprises Limited | 560.47 Billion INR | 99.693% |
Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.901% |
NATCO Pharma Limited | 10.53 Billion INR | 83.648% |
Suven Life Sciences Limited | 148.62 Million INR | -1058.778% |
Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 42.09% |
Strides Pharma Science Limited | 37.68 Billion INR | 95.429% |
Indoco Remedies Limited | 10.34 Billion INR | 83.348% |
Alpa Laboratories Limited | 307.12 Million INR | -460.75% |
Lasa Supergenerics Limited | 541.92 Million INR | -217.791% |
Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 55.761% |